Postprandial effects of the phosphodiesterase-5 (PDE-5) inhibitor tadalafil in type 2 diabetes patients: a randomised controlled trial

被引：0
作者：
Sjogren, L.
Olausson, J.
Strindberg, L.
Mobini, R.
Fogelstrand, P.
Hulten, L. Mattsson
Jansson, P. -A.
机构：
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
116
引用
收藏
页码：S55 / S56
页数：2
相关论文
共 50 条
  • [21] Synthesis and characterization of related substances and metabolite of tadalafil, a PDE-5 inhibitor
    Gilla, Goverdhan
    Anumula, Raghupathi Reddy
    Aalla, Sampath
    Vurimidi, Himabindu
    Ghanta, Mahesh Reddy
    ORGANIC COMMUNICATIONS, 2013, 6 (01) : 12 - 22
  • [22] Phosphodiesterase-5 (PDE-5) Inhibitors as Therapy for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury
    Kalyani, Priyanka
    Lippa, Sara M.
    Werner, J. Kent
    Amyot, Franck
    Moore, Carol B.
    Kenney, Kimbra
    Diaz-Arrastia, Ramon
    NEUROTHERAPEUTICS, 2023, 20 (06) : 1629 - 1640
  • [23] Tadalafil does not up-regulate the expression and activity of phosphodiesterase 5 (PDE-5) in the penis.
    Vernet, D
    Magee, TR
    Qian, A
    Nolazco, G
    Rajfer, J
    Gonzalez-Cadavid, NF
    JOURNAL OF UROLOGY, 2005, 173 (04) : 287 - 288
  • [24] Psychotherapy and phosphodiesterase-5 inhibitor in early rehabilitation after radical prostatectomy: a prospective randomised controlled trial
    Naccarato, A. M. E. P.
    Reis, L. O.
    Ferreira, U.
    Denardi, F.
    ANDROLOGIA, 2016, 48 (10) : 1183 - 1187
  • [25] Development of polymyositis after taking tadalafil, an oral phosphodiesterase-5 inhibitor
    Thompson, B.
    Pratt, A.
    Griffiths, B.
    RHEUMATOLOGY, 2007, 46 : I72 - I72
  • [26] Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
    Gheorghiu, Oana Ramona Catalina
    Ciobanu, Anne Marie
    Gutu, Claudia Maria
    Chitescu, Carmen Lidia
    Costea, Giorgiana Valentina
    Anghel, Daniela Madalina
    Vlasceanu, Ana Maria
    Baconi, Daniela Luiza
    MOLECULES, 2023, 28 (10):
  • [27] PILOT STUDY OF PHOSPHODIESTERASE-5 INHIBITOR (PDE-5) TO INCREASE INTRATUMORAL CONCENTRATION OF CARBOPLATIN IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS AND BRAIN METASTASES
    Phuphanich, Surasak
    Hu, Jethro
    Rudnick, Jeremy
    Chu, Ray
    Yu, John
    Naruse, Robert
    Ljubimova, Julia
    Sanchez, Cherry
    Guevarra, Almar
    Naor, Rebecca
    Black, Keith
    NEURO-ONCOLOGY, 2012, 14 : 83 - 83
  • [28] Phosphodiesterase type 5 (PDE-5) inhibitors in controlling symptomatic esophageal hypercontractility
    Agrawal, A
    Hila, A
    Tatuian, R
    Mainie, I
    Freeman, J
    Castell, DO
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (10) : S19 - S19
  • [29] Safety and efficacy of avanafil, a new phosphodiesterase type-5 (PDE-5) inhibitor for treating erectile dysfunction
    Kaufman, JM
    Dietrich, JW
    JOURNAL OF UROLOGY, 2006, 175 (04) : 299 - 299
  • [30] Phosphodiesterase-5 (PDE-5) is up-regulated in cirrhotic rat livers; Potential role for PDE-5 inhibitors in reducing the increased intrahepatic vascular tone in cirrhosis
    Loureiro-Silva, M
    Iwakiri, Y
    Abraldes, JG
    Haq, O
    Groszmann, RJ
    HEPATOLOGY, 2004, 40 (04) : 271A - 271A
12345